All reports

KCE Reports 343C (2021) During the past twenty years, a number of cancer treatments considered innovative have been introduced, such as monoclonal antibodies and immunotherapies. But what exactly should we expect from a new cancer treatment? That it prolongs life and/or that it improves quality of life.

KCE Reports 288C (2017) For several years, KCE has been doing substantive work to improve the transparency of decisions regarding the reimbursement of new treatments. This report is devoted to the article 81 convention system. This is a parallel procedure for reimbursement access that can be implemented when one wants to make available to patients a drug around which some uncertainties still persist, such as a not (yet) proven efficiency.